APPLICATIONS OF TECHNOLOGY:
- Breast cancer biomarker
- Drug development
- High sensitivity and specificity
- Could improve diagnosis and determine treatment options
- Could serve as a molecular target in developing anti-cancer medications
- Potential molecular target of cancer progression in other organs
The Patent Cooperation Treaty (PCT) patent application for this technolgy has been published (WO 2010/148370) and is available at www.wipo.int.
Mina Bissell and colleagues at Berkeley Lab have shown that 14-3-3 sigma expression correlates with acquisition of tumorigenicity and invasiveness, and that 14-3-3 sigma coordinates directional cell migration by directly inhibiting actin polymerization (in vitro and in situ) downstream of canonical signaling pathways, thus defining regions of actin assembly within cells. By immunohistochemical analysis, 14-3-3 sigma emerged as a highly sensitive and specific basal breast cancer biomarker which, when present, correlates with metastasis and poor outcome in independent patient cohorts. These data suggest that targeting 14-3-3 sigma-related actin cytoskeletal dynamics may benefit patients having the basal-like breast cancer subtype.
STATUS: Published PCT Patent Application WO 2010/148370 available at www.wipo.int.
SEE THESE OTHER BERKELEY LAB TECHNOLOGIES IN THIS FIELD:
REFERENCE NUMBER: IB-2594